Hungary and Russia are in advanced talks on licensing production of the Russian Sputnik V COVID-19 vaccine in Hungary, Reuters news agency reported on Tuesday.
Production under the deal could start from the end of 2022, Hungary's foreign minister said.
Hungary has widely used the Russian Sputnik vaccine during the pandemic even though it has not been approved by the European Medicines Agency.
Anivive Lifesciences receives USD20m in funding from Leonid Capital Partners
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment
hVIVO signs LOI for landmark Phase 3 whooping cough vaccine trial with ILiAD Biotechnologies
Abyssinia Biosciences signs collaborative agreement with Cordance Medical
hVIVO completes pilot study for hMPV challenge model
Merck's Gardasil approved for males in China
Brii Bio acquires BRII-179 IP rights
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Sanofi's combination vaccine candidates for flu and COVID-19 get Fast Track Designation
hVIVO secures GBP11.5m RSV contract
Novavax sells Czech manufacturing site to Novo Nordisk for USD200m
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine